--(BUSINESS WIRE)--Delix Therapeutics ... newest neuroplastogen developmental candidate, DLX-159, an orally bioavailable, non-hallucinogenic small molecule that promotes rapid and enduring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results